8-K: Acelyrin Prioritizes Lonigutamab, Reports Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa, and Announces Workforce Reduction

Acelyrin will focus on its lonigutamab program for thyroid eye disease, while reporting positive Phase 3 results for izokibep in hidradenitis suppurativa and implementing a workforce reduction of approximately 33%.

Summary

• Acelyrin has announced a strategic shift to prioritize the development of lonigutamab for thyroid eye disease (TED).
• The company's Phase 3 trial of izokibep in hidradenitis suppurativa (HS) met its primary endpoint, showing a statistically significant improvement over placebo.
• Despite positive results for izokibep in HS and psoriatic arthritis (PsA), Acelyrin will suspend new investment in these indications.
• A workforce reduction of approximately 33%, or about 40 employees, is part of the restructuring plan.
• The company expects to incur approximately $4.5 million in cash-based expenses related to employee severance payments and benefits.
• Acelyrin's cash runway is projected to extend to mid-2027, which will fund the lonigutamab Phase 3 trials and the ongoing izokibep trials.
• The company's cash, cash equivalents, and short-term marketable securities totaled $635.2 million as of June 30, 2024.
• Research and development expenses for the second quarter of 2024 were $76.4 million, compared to $30.0 million for the same period in 2023.
• The net loss for the quarter ended June 30, 2024, was $85.7 million, compared to $26.0 million for the same period in 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the positive Phase 3 data for izokibep and the strategic focus on lonigutamab, but tempered by the workforce reduction and increased net loss. The company is making strategic decisions to focus on its most promising program, which is generally viewed positively by investors.

Positives

• The Phase 3 trial of izokibep in HS showed statistically significant positive results, meeting its primary endpoint.
• The company is prioritizing lonigutamab, which has the potential to address unmet needs in thyroid eye disease.
• The strategic shift and workforce reduction are expected to extend the company's cash runway to mid-2027.
• The company has a strong cash position of $635.2 million as of June 30, 2024.
• The company is moving directly into a Phase 3 program for lonigutamab, potentially with concurrent trials, which is anticipated to be initiated in the first quarter of 2025.

Negatives

• Acelyrin is suspending new investment in the development of izokibep for hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.
• The company is reducing its workforce by approximately 33%, which will result in the departure of approximately 40 employees.
• The company expects to incur approximately $4.5 million in cash-based expenses related to employee severance payments and benefits.
• The company has stopped further development of the SLRN-517 program.
• The net loss for the quarter ended June 30, 2024, was $85.7 million, compared to $26.0 million for the same period in 2023.

Risks

• The company may not be able to successfully implement the restructuring plan as currently contemplated.
• The actual charges and cash expenditures associated with the restructuring plan may be higher than anticipated.
• The company may not achieve projected cost savings in connection with the restructuring plan.
• The company may experience unintended consequences from the restructuring plan that may impact its business.
• The successful completion of development and regulatory activities with respect to lonigutamab in thyroid eye disease is not guaranteed.
• The company faces risks associated with maintaining and defending intellectual property protection.
• The company's actual results may differ materially from those anticipated in forward-looking statements.

Future Outlook

Acelyrin expects its current cash resources to fund operations through mid-2027, including the ongoing Phase 2 trial and two planned Phase 3 trials for lonigutamab in TED, the ongoing izokibep Phase 3 trial in uveitis, and the completion of the ongoing izokibep HS and PsA trials. The company plans to initiate a Phase 3 program for lonigutamab in the first quarter of 2025.

Management Comments

• Mina Kim, Chief Executive Officer of ACELYRIN, stated that while the positive HS data and previously announced psoriatic arthritis data support a path to approval for izokibep, a program of this breadth and size is best brought to market by a larger organization.
• Mina Kim also expressed excitement about the opportunity for lonigutamab to address unmet needs of patients with TED.
• Mina Kim noted that the strategic shift allows the company to extend its cash runway to mid-2027 and fully fund both Phase 3 trials for lonigutamab.
• Shoaib Ugradar, MD, expressed encouragement by the patient-centered approach to developing lonigutamab and looks forward to participating in the pivotal trials.

Industry Context

This announcement reflects a trend in the biopharmaceutical industry where companies often prioritize their most promising programs and seek partnerships for others. The focus on lonigutamab aligns with the growing interest in treatments for thyroid eye disease, while the decision to suspend new investment in izokibep suggests a strategic realignment of resources.

Comparison to Industry Standards

• The reported 33% HiSCR75 response rate for izokibep in HS at 12 weeks is comparable to other IL-17 inhibitors in the market, such as Cosentyx and Taltz, which have shown similar efficacy in clinical trials.
• The decision to prioritize lonigutamab in TED is consistent with the industry's focus on developing targeted therapies for specific autoimmune conditions, similar to how Horizon Therapeutics' Tepezza has become a standard of care for TED.
• The workforce reduction of 33% is a significant restructuring, which is not uncommon in the biotech industry when companies need to conserve cash and focus on key programs. This is similar to other companies that have undergone restructuring to extend their cash runway.
• The company's cash runway projection to mid-2027 is a positive sign for investors, indicating that the company has sufficient funds to complete its key clinical trials, which is a common benchmark for biotech companies.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the strategic focus on lonigutamab and the extended cash runway, but negatively to the workforce reduction and increased net loss.
• Employees will be impacted by the workforce reduction, with approximately 40 employees losing their jobs.
• Patients with thyroid eye disease may benefit from the accelerated development of lonigutamab.
• Patients with hidradenitis suppurativa and psoriatic arthritis may experience a delay in the availability of izokibep due to the suspension of new investment in these indications.
• Suppliers and vendors may be affected by the company's restructuring and changes in priorities.

Next Steps

• Acelyrin will complete the ongoing PsA and HS trials for izokibep.
• The company will continue the Phase 2b/3 trial of izokibep in uveitis, with top-line data expected in the fourth quarter of 2024.
• Acelyrin plans to initiate a Phase 3 program for lonigutamab in the first quarter of 2025.
• The company will hold an EOP2 meeting with the FDA later this year and host an investor presentation to provide additional Phase 2 data and details for the planned Phase 3 program.
• The company will implement the workforce reduction and associated restructuring plan.

Key Dates

Keywords

lonigutamab, izokibep, thyroid eye disease, hidradenitis suppurativa, psoriatic arthritis, clinical trials, workforce reduction, restructuring, biopharma, immunology